Matricelf Ltd, a biotechnology company, develops a platform for autologous tissue engineering for various medical conditions. The company's regenerative medicine platform intends to cure a range of medical conditions, including spinal cord injuries, age-related macular degeneration, Parkinson's disease, and myocardial infarction, as well as for 3D bioprinting. The company has a strategic collaboration with Sheba Medical Center for the development and clinical advancement of its neural tissue implant product for the treatment of spinal cord injury; and CiRA Foundation for the development of regenerative manufacturing technologies and the evaluation of iPSC-based neural tissue engineering for therapeutic applications. The company was incorporated in 2019 and is based in Ness Ziona, Israel.
Frequently asked questions
What sector does Matricelf Ltd (MTLF) operate in?
Matricelf Ltd belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Matricelf Ltd (MTLF) current stock price?
As of the latest data, Matricelf Ltd stock price is ₪2.71, with a previous close of ₪2.60. Matricelf Ltd gained ₪0.11 in the last trading session, representing a 4.28% increase.
What is Matricelf Ltd (MTLF) current market capitalization?
Matricelf Ltd market cap is approximately 82.06 million.
Does Matricelf Ltd (MTLF) pay dividends?
No. Matricelf Ltd does not pay a dividend.
What is Matricelf Ltd (MTLF) beta (volatility) score?
Matricelf Ltd has a beta of 0.320, indicating lower volatility than the overall market.
